AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14990394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 11359552 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions aimed at reducing medical errors (specific interventions not detailed)
Number of subjects: 13
Study 11359552 — intervention group
Group type: COMPARATOR
Intervention: Control arms (no specific intervention detailed)
Number of subjects: 13
Study 11359552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized studies (24 studies evaluated for comparison)
Number of subjects: 13
Study 9064950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary iloprost (ILO) 0.5 ng kg‐1 min‐1
Number of subjects: 0
Study 9064950 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iloprost (ILO) 2 ng kg‐1 min‐1
Number of subjects: 0
Study 9064950 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (PAPA) intracoronary
Number of subjects: 0
Study 1473306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ramipril 5 mg plus hydrochlorothiazide 25 mg
Number of subjects: 165
Study 1473306 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5 mg monotherapy
Number of subjects: 165
Study 1473306 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg monotherapy
Number of subjects: 165
Study 6322827 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical analgesia (4% lignocaine 2 ml)
Number of subjects: 48
Study 6322827 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia (1.5%)
Number of subjects: 48
Study 6322827 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (10 mg kg‐1)
Number of subjects: 48
Study 30536632 — intervention group
Group type: COMPARATOR
Intervention: Orally dispersible tablet (ODT) of racemic praziquantel (rac-PZQ) at 40 mg/kg
Number of subjects: 68
Study 30536632 — intervention group
Group type: COMPARATOR
Intervention: Orally dispersible tablet (ODT) of levo praziquantel (L-PZQ) at 20 mg/kg
Number of subjects: 68
Study 30536632 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally dispersible tablet (ODT) of levo praziquantel (L-PZQ)
Number of subjects: 68
Study 29602534 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion recognition training
Number of subjects: 0
Study 29602534 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention control
Number of subjects: 0
Study 26561047 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (25 to 50 mg/d)
Number of subjects: 30
Study 26561047 — intervention group
Group type: COMPARATOR
Intervention: baseline to 2 years (donors)
Number of subjects: 30
Study 26561047 — intervention group
Group type: COMPARATOR
Intervention: baseline to 2 years (recipients)
Number of subjects: 30
Study 24451613 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood smoke exposure
Number of subjects: 20
Study 24451613 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 20
Study 22075020 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal plus isoflurane anesthesia (SI)
Number of subjects: 45
Study 22075020 — intervention group
Group type: COMPARATOR
Intervention: Spinal plus desflurane anesthesia (SD)
Number of subjects: 45
Study 22075020 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia alone (S)
Number of subjects: 45
Study 21140355 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal hemodiafiltration
Number of subjects: 24
Study 21140355 — intervention group
Group type: COMPARATOR
Intervention: Low-flux bicarbonate dialysis
Number of subjects: 24
Study 17215654 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual detailing intervention
Number of subjects: 0
Study 17215654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group detailing intervention
Number of subjects: 0
Study 17215654 — intervention group
Group type: COMPARATOR
Intervention: Mailed guideline intervention
Number of subjects: 0
Study 15465887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg oral)
Number of subjects: 11
Study 15465887 — intervention group
Group type: COMPARATOR
Intervention: Control (no ibuprofen)
Number of subjects: 11
Study 12216077 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened women (28,099)
Number of subjects: 28
Study 12216077 — intervention group
Group type: COMPARATOR
Intervention: Invited but declined screening (39,425)
Number of subjects: 28
Study 12216077 — intervention group
Group type: COMPARATOR
Intervention: Not invited (97,294)
Number of subjects: 28
Study 10705093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cancer information leaflet
Number of subjects: 259
Study 10705093 — intervention group
Group type: COMPARATOR
Intervention: Control groups (two control groups)
Number of subjects: 259
Study 10705093 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge questionnaire
Number of subjects: 259
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in LVP
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in LVV
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in MOL
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in RVP
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine in LVP
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine in MOL
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in LVP
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in LVV
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in MOL
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in RVP
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma dopamine
Number of subjects: 69
Study 8566937 — intervention group
Group type: EXPERIMENTAL
Intervention: cAMP levels in all groups
Number of subjects: 69
Study 8566937 — intervention group
Group type: COMPARATOR
Intervention: Control group beta-adrenoceptor density
Number of subjects: 69
Study 2025378 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 146
Study 2025378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 146
Study 2025378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 7346742 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (MPH)
Number of subjects: 12
Study 7346742 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (AMP)
Number of subjects: 12
Study 7346742 — intervention group
Group type: COMPARATOR
Intervention: placebo (PB)
Number of subjects: 12
Study 30842175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 757
Study 28117270 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised self-injection with an empty syringe
Number of subjects: 60
Study 28117270 — intervention group
Group type: COMPARATOR
Intervention: Education only (control)
Number of subjects: 60
Study 26275429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 3517
Study 26275429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 3517
Study 26275429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3517
Study 26275429 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (both doses)
Number of subjects: 3517
Study 24405624 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA-GROUP (before TKA)
Number of subjects: 13
Study 24405624 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA-GROUP (after TKA)
Number of subjects: 13
Study 24405624 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA-GROUP (pre-operative to post-operative)
Number of subjects: 13
Study 24405624 — intervention group
Group type: COMPARATOR
Intervention: CONTROL-GROUP
Number of subjects: 13
Study 22276957 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (KEY Laser(®) 3)
Number of subjects: 78
Study 22276957 — intervention group
Group type: COMPARATOR
Intervention: Sonic debridement (Sonicflex(®) 2003 L)
Number of subjects: 78
Study 22276957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Er:YAG laser and Sonic debridement)
Number of subjects: 78
Study 19054817 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 744
Study 17584198 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler Echo, Doppler myocardial imaging, Strain rate imaging, transthoracic CFR after dipyridamole infusion, and brachial artery vasodilatation measurement in SSc patients
Number of subjects: 33
Study 17584198 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic CFR
Number of subjects: 33
Study 17584198 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial flow‐mediated dilatation
Number of subjects: 33
Study 17584198 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR and endothelial function
Number of subjects: 33
Study 17584198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest-CT
Number of subjects: 33
Study 17584198 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological antibodies analysis
Number of subjects: 33
Study 17584198 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic pulmonary pressure measurement
Number of subjects: 33
Study 15028048 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrially tracked pacing
Number of subjects: 10
Study 15028048 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-responsive pacing
Number of subjects: 10
Study 15028048 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate pacing
Number of subjects: 10
Study 11311844 — intervention group
Group type: EXPERIMENTAL
Intervention: Games and shows aimed at a child's developmental level
Number of subjects: 0
Study 11311844 — intervention group
Group type: COMPARATOR
Intervention: Didactic information alone
Number of subjects: 0
Study 9570235 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Chinese herbal medication (CH-100), five tablets thrice daily
Number of subjects: 40
Study 9570235 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets, five tablets thrice daily
Number of subjects: 40
Study 8072815 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently with DTPa and IPV
Number of subjects: 439
Study 3211485 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% suprofen solution
Number of subjects: 0
Study 30539231 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowering plants in the coronary care ward during index hospitalisation
Number of subjects: 122
Study 30539231 — intervention group
Group type: COMPARATOR
Intervention: No plants (control) in the coronary care ward during index hospitalisation
Number of subjects: 122
Study 28460263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure mapping system
Number of subjects: 190
Study 28460263 — intervention group
Group type: COMPARATOR
Intervention: Standard pressure ulcer prevention care (Control)
Number of subjects: 190
Study 26001545 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR), 25% CR from baseline energy requirements
Number of subjects: 46
Study 26001545 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction combined with exercise (CR+exercise), 12.5% CR and 12.5% through aerobic exercise
Number of subjects: 46
Study 26001545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet until 15% reduction in body weight followed by weight maintenance diet
Number of subjects: 46
Study 26001545 — intervention group
Group type: COMPARATOR
Intervention: Control group, healthy weight maintenance
Number of subjects: 46
Study 22591190 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol dose (intended peak breath alcohol concentration of 0.04%)
Number of subjects: 59
Study 22591190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 20186830 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide 130 mg/m(2) on Days 1 through 14 every 4 weeks for 12 cycles (C arm)
Number of subjects: 1146
Study 20186830 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) on Days 1 and 8 every 4 weeks for 12 cycles (CMF arm)
Number of subjects: 1146
Study 20186830 — intervention group
Group type: COMPARATOR
Intervention: Levamisole 5 mg weekly for 48 weeks (levamisole arm)
Number of subjects: 1146
Study 20186830 — intervention group
Group type: COMPARATOR
Intervention: No systemic therapy (control arm)
Number of subjects: 1146
Study 17277584 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 12
Study 17277584 — intervention group
Group type: COMPARATOR
Intervention: Normal activity (Control)
Number of subjects: 12
Study 15892894 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 40
Study 15892894 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 40
Study 11856088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole
Number of subjects: 175
Study 10451908 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment
Number of subjects: 38
Study 10451908 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38
Study 7875466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal balloon distentions
Number of subjects: 32
Study 7875466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal electrical nerve stimulation (15 Hz, 100 microseconds)
Number of subjects: 32
Study 7875466 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic transcutaneous electrical nerve stimulation (100 Hz, 100 microseconds)
Number of subjects: 32
Study 2092026 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB)
Number of subjects: 29
Study 2092026 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (combined with ranitidine for ulcer healing)
Number of subjects: 29
Study 2092026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy with both amoxycillin and TDB
Number of subjects: 29
Study 350564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 20
Study 350564 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 20
Study 31386976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy on sand surface
Number of subjects: 16
Study 31386976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy at faster horse walking speed (30%)
Number of subjects: 16
Study 31386976 — intervention group
Group type: COMPARATOR
Intervention: Hippotherapy on asphalt surface
Number of subjects: 16
Study 31386976 — intervention group
Group type: COMPARATOR
Intervention: Hippotherapy at slow (self-selected) horse walking speed
Number of subjects: 16
Study 29629886 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 910
Study 29629886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 910
Study 29629886 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 910
Study 29629886 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiemetic prophylaxis
Number of subjects: 910
Study 26610716 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive outcome condition (adult completed the task successfully)
Number of subjects: 84
Study 26610716 — intervention group
Group type: COMPARATOR
Intervention: Negative outcome condition (adult did not complete the task successfully)
Number of subjects: 84
Study 25066558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild thrombocytopenia (nadir platelet count 100-149 × 10(9)/L)
Number of subjects: 7435
Study 25066558 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe thrombocytopenia (nadir platelet count <100 × 10(9)/L)
Number of subjects: 7435
Study 25066558 — intervention group
Group type: COMPARATOR
Intervention: No thrombocytopenia
Number of subjects: 7435
Study 25066558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild thrombocytopenia
Number of subjects: 7435
Study 25066558 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe thrombocytopenia
Number of subjects: 7435
Study 22678087 — intervention group
Group type: EXPERIMENTAL
Intervention: QT prolongation on ECG immediately following SAH
Number of subjects: 413
Study 22678087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachycardia on baseline ECG
Number of subjects: 413
Study 22678087 — intervention group
Group type: EXPERIMENTAL
Intervention: QT prolongation on ECG during the vasospasm risk period
Number of subjects: 413
Study 22678087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachycardia and ST changes
Number of subjects: 413
Study 20685401 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing with ventricular backup at 60 beats/min
Number of subjects: 1030
Study 20685401 — intervention group
Group type: COMPARATOR
Intervention: Ventricular backup pacing at 40 beats/min
Number of subjects: 1030
Study 18569863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) followed by 10 days of prasugrel 10 mg MD (n = 16)
Number of subjects: 39
Study 18569863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg MD (n = 19)
Number of subjects: 39
Study 18569863 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg MD (control)
Number of subjects: 39
Study 15779502 — intervention group
Group type: EXPERIMENTAL
Intervention: CODAS formulation of verapamil (200 mg)
Number of subjects: 466
Study 11867940 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH test in obese patients (13 total: 5 men and 8 women)
Number of subjects: 39
Study 11867940 — intervention group
Group type: COMPARATOR
Intervention: CRH test in control subjects (18 total: 9 men and 9 women)
Number of subjects: 39
Study 11867940 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH administration in obese subjects
Number of subjects: 39
Study 11867940 — intervention group
Group type: COMPARATOR
Intervention: CRH administration in control subjects
Number of subjects: 39
Study 11867940 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH test in obese patients
Number of subjects: 39
Study 11867940 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH test in both groups
Number of subjects: 39
Study 12953999 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 8
Study 12953999 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 8
Study 7614110 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 30
Study 7614110 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 30
Study 7614110 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 30
Study 2183758 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Deep Muscle Relaxation Training
Number of subjects: 88
Study 2183758 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated Exposure
Number of subjects: 88
Study 2183758 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical Intention
Number of subjects: 88
Study 7416212 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (Depo‐Provera)
Number of subjects: 48
Study 7416212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29803203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei (108 cfu daily for 8 weeks)
Number of subjects: 40
Study 29803203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin capsules for 8 weeks)
Number of subjects: 40
Study 26773206 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat anticipation condition (anticipation of public speaking)
Number of subjects: 168
Study 26773206 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 168
Study 25794163 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-naïve
Number of subjects: 107
Study 25794163 — intervention group
Group type: COMPARATOR
Intervention: CMV+ viremic
Number of subjects: 107
Study 25794163 — intervention group
Group type: COMPARATOR
Intervention: CMV+ aviremic
Number of subjects: 107
Study 25794163 — intervention group
Group type: COMPARATOR
Intervention: CMV status
Number of subjects: 107
Study 23361469 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 100
Study 23361469 — intervention group
Group type: COMPARATOR
Intervention: Facemask with oropharyngeal airway (FM)
Number of subjects: 100
Study 21381967 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing Grand Theft Auto IV for a total of 12 hours over a period of 3 weeks
Number of subjects: 135
Study 21381967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no game played)
Number of subjects: 135
Study 19531876 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation with intent to imitate (OTI)
Number of subjects: 13
Study 19531876 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitation with real-time virtual avatar feedback
Number of subjects: 13
Study 19531876 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation with intent to imitate actions performed by the virtual avatar
Number of subjects: 13
Study 19531876 — intervention group
Group type: COMPARATOR
Intervention: Imitation with virtual avatar feedback
Number of subjects: 13
Study 18605145 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback training on time-judgment task
Number of subjects: 0
Study 18605145 — intervention group
Group type: COMPARATOR
Intervention: No feedback training on time-judgment task
Number of subjects: 0
Study 16360445 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655
Study 16360445 — intervention group
Group type: COMPARATOR
Intervention: Autologous rectus fascial sling
Number of subjects: 655
Study 16360445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical procedures
Number of subjects: 655
Study 16360445 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative urodynamic studies
Number of subjects: 655
Study 11887517 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush
Number of subjects: 59